Fiona Nussey

2.9k total citations
21 papers, 380 citations indexed

About

Fiona Nussey is a scholar working on Oncology, Reproductive Medicine and Surgery. According to data from OpenAlex, Fiona Nussey has authored 21 papers receiving a total of 380 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 12 papers in Reproductive Medicine and 5 papers in Surgery. Recurrent topics in Fiona Nussey's work include Ovarian cancer diagnosis and treatment (12 papers), Endometrial and Cervical Cancer Treatments (5 papers) and PARP inhibition in cancer therapy (5 papers). Fiona Nussey is often cited by papers focused on Ovarian cancer diagnosis and treatment (12 papers), Endometrial and Cervical Cancer Treatments (5 papers) and PARP inhibition in cancer therapy (5 papers). Fiona Nussey collaborates with scholars based in United Kingdom, Australia and Japan. Fiona Nussey's co-authors include Tzyvia Rye, Robert L. Hollis, C. Simon Herrington, Charlie Gourley, Melanie Mackean, Michael Churchman, Robert Leonard, David Miles, Robert Thomas and Bárbara Stanley and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and BMJ.

In The Last Decade

Fiona Nussey

20 papers receiving 372 citations

Peers

Fiona Nussey

ONCOL

GENET

Alessia Romito Italy

Valentina Zanfagnin United States

Sushmita Gordhandas United States

Erik Škof Slovenia

Luis Z. Blanco United States

Maria-Pilar Barretina-Ginesta Spain

Susanne Markmann Germany

H.W.H.M. van der Putten Netherlands

Jennifer McLachlan United Kingdom

Grazia Artioli Italy

Alessia Romito Italy

Fiona Nussey

209 ×1.1

118 ×0.7

ONCOL

98 ×1.1

47 ×0.6

30 ×0.4

GENET

Citations per year, relative to Fiona Nussey Fiona Nussey (= 1×) peers Alessia Romito

Countries citing papers authored by Fiona Nussey

Since Specialization

Citations

This map shows the geographic impact of Fiona Nussey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fiona Nussey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fiona Nussey more than expected).

Fields of papers citing papers by Fiona Nussey

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fiona Nussey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fiona Nussey. The network helps show where Fiona Nussey may publish in the future.

Co-authorship network of co-authors of Fiona Nussey

This figure shows the co-authorship network connecting the top 25 collaborators of Fiona Nussey. A scholar is included among the top collaborators of Fiona Nussey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fiona Nussey. Fiona Nussey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Thomson, John P., Robert L. Hollis, Michael Churchman, et al.. (2023). Whole exome sequencing of low grade serous ovarian carcinoma identifies genomic events associated with clinical outcome. Gynecologic Oncology. 174. 157–166. 8 indexed citations

Hollis, Robert L., Bárbara Stanley, John P. Thomson, et al.. (2021). Integrated molecular characterisation of endometrioid ovarian carcinoma identifies opportunities for stratification. npj Precision Oncology. 5(1). 47–47. 16 indexed citations

Hollis, Robert L., Samantha L. Hopkins, Clare Bartos, et al.. (2021). Clinicopathological Determinants of Recurrence Risk and Survival in Mucinous Ovarian Carcinoma. Cancers. 13(22). 5839–5839. 10 indexed citations

Hollis, Robert L., John P. Thomson, Bárbara Stanley, et al.. (2020). Molecular stratification of endometrioid ovarian carcinoma predicts clinical outcome. Nature Communications. 11(1). 4995–4995. 83 indexed citations

Irodi, Aparna, Tzyvia Rye, Karl E. Herbert, et al.. (2020). Patterns of clinicopathological features and outcome in epithelial ovarian cancer patients: 35 years of prospectively collected data. BJOG An International Journal of Obstetrics & Gynaecology. 127(11). 1409–1420. 34 indexed citations

Hollis, Robert L., Juliet Carmichael, Alison Meynert, et al.. (2019). Clinical and molecular characterization of ovarian carcinoma displaying isolated lymph node relapse. American Journal of Obstetrics and Gynecology. 221(3). 245.e1–245.e15. 20 indexed citations

Hollis, Robert L., Bárbara Stanley, Yasushi Iida, et al.. (2019). Hormone receptor expression patterns define clinically meaningful subgroups of endometrioid ovarian carcinoma. Gynecologic Oncology. 155(2). 318–323. 22 indexed citations

Stanley, Bárbara, Robert L. Hollis, Tzyvia Rye, et al.. (2018). Endocrine treatment of high grade serous ovarian carcinoma; quantification of efficacy and identification of response predictors. Gynecologic Oncology. 152(2). 278–285. 22 indexed citations

Hollis, Robert L., Alison Meynert, Michael Churchman, et al.. (2018). Enhanced response rate to pegylated liposomal doxorubicin in high grade serous ovarian carcinomas harbouring BRCA1 and BRCA2 aberrations. BMC Cancer. 18(1). 16–16. 16 indexed citations

10.

Spiliopoulou, Pavlina, C. Bell, D. Stirling, et al.. (2018). Routine germline BRCA1 and BRCA2 testing in patients with ovarian carcinoma: analysis of the Scottish real‐life experience. BJOG An International Journal of Obstetrics & Gynaecology. 125(11). 1451–1458. 19 indexed citations

11.

Nussey, Fiona, et al.. (2018). Comparative efficacy and tolerability of the PARP inhibitors, olaparib 300 mg tablets BID, niraparib 300 mg capsules QD and rucaparib 600 mg tablets BID as maintenance treatment in BRCA -mutated ( BRCA m) platinum-sensitive relapsed ovarian. Gynecologic Oncology. 149. 43–44. 6 indexed citations

12.

Lyall, Marcus J., Melanie Mackean, Fiona Nussey, et al.. (2018). Diurnal profile of interstitial glucose following dexamethasone prophylaxis for chemotherapy treatment of gynaecological cancer. Diabetic Medicine. 35(11). 1508–1514. 7 indexed citations

13.

Nussey, Fiona, et al.. (2017). Comparative Efficacy And Safety Of Olaparib 300 Mg Tablets Bid And Niraparib 300 Mg Tablets QD As Maintenance Treatment After Response To Chemotherapy In Patients With Platinum-Sensitive Relapsed Germline BRCA-Mutated Ovarian Cancer (PSROC). Value in Health. 20(9). A412–A412. 1 indexed citations

14.

McKay, Neil D, et al.. (2013). Dermatomyositis as presenting feature of ovarian cancer, treated with neo-adjuvant chemotherapy and interval debulking surgery. PubMed. 6. 13–15. 10 indexed citations

15.

Bakri, Nur Amalina Che, Patricia Roxburgh, Muhammad Imtiaz Khan, et al.. (2013). Chemotherapy-induced myelosuppression in ovarian cancer patients with germline BRCA1/2 mutations: A case control study.. Journal of Clinical Oncology. 31(15_suppl). 5571–5571.

16.

Camidge, D. Ross, James Oliver, Ben Attwood, et al.. (2007). The impact of prognosis without treatment on doctors' and patients' resource allocation decisions and its relevance to new drug recommendation processes. British Journal of Clinical Pharmacology. 65(2). 224–229. 6 indexed citations

17.

Camidge, D. Ross, Andrew Walker, James Oliver, et al.. (2005). Prognosis without treatment as a modifier in health economic assessments. BMJ. 330(7504). 1382–1384. 10 indexed citations

18.

Nussey, Fiona, et al.. (2004). Dose-finding study of the combination of oral idarubicin and oral capecitabine in the treatment of locally advanced or advanced breast cancer. European Journal of Cancer Supplements. 2(3). 137–137. 1 indexed citations

19.

Leonard, Robert, et al.. (2003). Impact of neutropenia on delivering planned adjuvant chemotherapy: UK audit of primary breast cancer patients. British Journal of Cancer. 89(11). 2062–2068. 82 indexed citations

20.

Dawson, L., et al.. (2001). Osteonecrosis of the femoral head following adjuvant chemotherapy for breast cancer. The Breast. 10(5). 447–449. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact